PEPG - PepGen Ltd

PEPG - PepGen Ltd

https://pepgen.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of PepGen Inc. ( PEPG ) Shareholders - PepGen ( NASDAQ:PEPG )

Benzinga • 1 month ago • score: -0.07

NEW YORK, Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in PepGen Inc. ( "PepGen Inc." or the "Company" ) PEPG of a class action securities lawsuit.

PEPGEN ( PEPG ) FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds PepGen Investors of the August 8th Deadline and Encourages Investors to Contact the Firm - PepGen ( NASDAQ:PEPG )

Benzinga • 1 month, 1 week ago • score: -0.04

Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In PepGen ( PEPG ) To Contact Them Directly To Discuss Their Options

PepGen Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 8, 2025 Deadline to file Lead Plaintiff Motion. - PepGen ( NASDAQ:PEPG )

Benzinga • 1 month, 1 week ago • score: -0.08

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- The Portnoy Law Firm advises PepGen Inc. ( "PepGen" or the "Company" ) PEPG investors of a class action representing investors that bought securities between ...

PepGen ( PEPG ) Q2 Loss Narrows 19.5%

Motley Fool • 1 month, 1 week ago • score: 0.25

PepGen ( NASDAQ:PEPG ) , a biotechnology company focused on developing oligonucleotide-based therapies for neuromuscular diseases, released its earnings for the second quarter of 2025 on August 7, 2025. The biggest news was a GAAP net loss per share of $ ( 0.70 ) , which was better than the ...

PEPG DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages PepGen Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 8 Deadline in Securities Class Action - PEPG - PepGen ( NASDAQ:PEPG )

Benzinga • 1 month, 1 week ago

NEW YORK, Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of PepGen Inc. PEPG between March 7, 2024 and March 3, 2025, both dates inclusive ( the "Class Period" ) , of the important August 8, 2025 lead plaintiff ...

PEPGEN ( PEPG ) URGENT DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds PepGen Investors of the August 8th Deadline and Encourages Investors to Contact the Firm - PepGen ( NASDAQ:PEPG )

Benzinga • 1 month, 1 week ago • score: -0.04

Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In PepGen ( PEPG ) To Contact Them Directly To Discuss Their Options

PepGen Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; August 8, 2025 Deadline to file Lead Plaintiff Motion - PepGen ( NASDAQ:PEPG )

Benzinga • 1 month, 1 week ago • score: -0.08

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Aug. 05, 2025 ( GLOBE NEWSWIRE ) -- The Portnoy Law Firm advises PepGen Inc. ( "PepGen" or the "Company" ) PEPG investors of a class action representing investors that bought securities between ...

PepGen Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before August 8, 2025 to Discuss Your Rights - PEPG - PepGen ( NASDAQ:PEPG )

Benzinga • 1 month, 1 week ago • score: 0.00

NEW YORK, Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- The Gross Law Firm issues the following notice to shareholders of PepGen Inc. PEPG. Shareholders who purchased shares of PEPG during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

PEPGEN INC. ( NASDAQ: PEPG ) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds PepGen Inc. Investors of Upcoming Deadline - PepGen ( NASDAQ:PEPG )

Benzinga • 1 month, 1 week ago • score: 0.20

NEW YORK, Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds PepGen Inc. ( "PepGen" or the "Company" ) PEPG investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

PepGen Inc., a clinical-stage biotechnology company, is focused on the development of oligonucleotide therapeutics for use in the treatment of serious neurological and neuromuscular diseases. The company is headquartered in Cambridge, Massachusetts.

52W High

$10.05

52W Low

$0.88

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.17

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-3.12

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

0.65

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

0.27%

Institutions (25–75% balanced)

89.50%

Shares Outstanding

32,799,700

Float

14,527,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-2.96

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.86%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.0528

Previous

0.0417

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025